Dataset from A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

The purpose of this study is to evaluate if ibrutinib administered in combination with
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) improves the
clinical outcome in newly diagnosed patients with non-germinal center B-cell subtype (GCB) of
diffuse large B-cell lymphoma (DLBCL) selected by immunohistochemistry (IHC) or newly
diagnosed patients with activated B cell-like (ABC) subtype of DLBCL identified by gene
expression profiling (GEP) or both populations.